Inventiva achieves a major milestone by completing patient recruitment for its Phase IIb clinical study with lanifibranor in NASH

    NEXT STORY
    Oasmia completes its management team
    PREV STORY
    More former foster youth could succeed in school with $150,000 investment from United Way of the Lower Mainland
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas

    OSE-127 significantly decreases inflammation in colon biopsies from patients with inflammatory bowel diseases and ...

    author_avatar
    NASDAQ Market News

    Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study

    author_avatar
    NASDAQ Market News

    GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050

    author_avatar
    NASDAQ Market News